{"paper_id":"1f5d8435-c08d-43e9-a44f-a39ba72e60c9","body_text":"Abstract\nFollicle-stimulating hormone receptor (FSHR) is present on endothelial cells of blood vessels and endometrial glands of the proliferative and secretory endometrium. So far, the expression of FSHR in endometriosis has not been studied. We evaluated FSHR expression in 194 tissue specimens representing 3 relevant types of endometriosis: rectovaginal endometriotic nodules, ovarian endometriotic cysts, and peritoneal endometriotic implants. Specimens of normal endometrium were used as controls. Archival formalin-fixed and paraffin-embedded material was analyzed immunohistochemically with a highly specific monoclonal antihuman FSHR antibody using the peroxidase method. A robust vascular FSHR expression was found in all 194 patients, irrespective of the endometriosis lesion location. Follicle-stimulating hormone receptor was not detected in normal host tissues located more than 5 mm from the lesions. The endometriotic lymphatic vessels do not express FSHR. The density of FSHR-positive vessels in patients with rectovaginal endometriotic nodules was 46.0 ± 5.7 vessels/mm2. Similar values were obtained for ovarian endometriotic cysts and peritoneal endometriosis. The density of FSHR-positive vessels associated with the core of rectovaginal endometriotic nodules was 2-fold higher than that of the perilesional, adjacent normal host tissue (64.2 ± 8.2 vs 27.2 ± 3.2 vessels/mm2, respectively). Expression of FSHR was also detected either in endometriotic glandular epithelial cells, endometriotic stromal cells, or in both cell types (23%, 25%, and 21% of patients, respectively). Normal endometrium expressed FSHR predominately in basalis, in a cellular distribution dependent on hormonal environment. In conclusion, our data suggest novel FSHR expression in endometriotic lesions, qualitatively and quantitatively different from that of normal endometrium.\nSimilar content being viewed by others\nReferences\nAsante A, Taylor RN. Endometriosis: the role of neuroangiogenesis. Annu Rev Physiol. 2011;73:163–182.\nPearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385–394.\nVerit FF, Yucel O. Endometriosis, leiomyoma and adenomyosis: the risk of gynecologic malignancy. Asian Pac J Cancer Prev. 2013;14(10):5589–5597.\nBulun SE, Monsivais D, Kakinuma T, et al. Molecular biology of endometriosis: from aromatase to genomic abnormality. Semin Reprod Med. 2015;33(3):220–224.\nWhitlock JPJ. The regulation of cytochrome P-450 gene expression. Annu Rev Pharmacol Toxicol. 1986;26:333–369.\nLessey BA, Metzger DA, Haney AF, McCarty KS Jr. Immunohis-tochemical analysis of estrogen and progesterone receptors in endometriosis: comparison with normal endometrium during the menstrual cycle and the effect of medical therapy. Fertil Steril. 1989;51(3):409–415.\nBergqvist A, Fernö M. Estrogen and progesterone receptors in endometriotic tissue and endometrium: comparison according to localization and recurrence, Fertil Steril. 1993;60(1):63–68.\nFujishita A, Nakane PK, Koji T, et al. Expression of estrogen and progesterone receptors in endometrium and peritoneal endometriosis: an immunohistochemical and in situ hybridization study. Fertil Steril. 1997;67(5):856–864.\nNoble LS, E.R. Simpson ER, Johns A, Bulun SE. Aromatase expression in endometriosis. J Clin Endocrinol Metab. 1996;81(1):174–179.\nKitawaki J, Noguchi T, Amatsu T, et al. Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol Reprod. 1997;57(3):514–519.\nFerrero S, Remorgida V, Maganza C, et al. Aromatase and endometriosis: estrogens play a role. Ann NY Acad Sci. 2014;1317:17–23.\nKitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steriod Biochem Mol Biol. 2002;83(1–5):149–155.\nSimoni M, Gromoll J, Nieschlag E. The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocr Rev. 1997;18(6):739–773.\nVannier B, Loosfelt H, Meduri G, Pichon C, Milgrom E. Antihuman FSH receptor monoclonal antibodies: immunochemical and immunocytochemical characterization of the receptor. Biochemistry. 1996;35(5):1358–1366.\nRadu A, Pichon C, Camparo P, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010;363(17):1621–1630.\nSimionescu N, Simionescu M. The cardiovascular system. In: Weiss L, ed. Cell and Tissue Biology: A textbook of histology. 6th ed. Baltimore, Munchen: Urban & Schwarzenberg Inc; 1988:353–400.\nTang B, Gurpide E. Direct effect of gonadotropins on decidualization of human endometrial stroma cells. J Steroid Biochem Mol Biol. 1993;47(1–6):115–121.\nLa Marca A, Artenisio AC, Stabile G, Rivasi F, Volpe A. Evidence for cycle-dependent expression of follicle-stimulating hormone receptor in human endometrium. Gynecol Endocrinol. 2005;21(6):303–306.\nStilley JA, Christensen DE, Dahlem KB, et al. FSH receptor (FSHR) expression in human extragonadal reproductive tissues and the developing placenta, and the impact of its deletion on pregnancy in mice. Biol Reprod. 2014;91(3):1–15.\nMetzger DA, Olive DL, Haney AF. Limited hormonal responsiveness of ectopic endometrium: histologic correlation with intrauterine endometrium. Hum Pathol. 1988;19(12):1417–1424.\nVu Hai MT, Lescop P, Loosfelt H, Ghinea N. Receptor-mediated transcytosis of follicle-stimulating hormone through the rat testicular microvasculature. Biol Cell. 2004;96(2):133–144.\nBulun SE, Cheng YH, Yin P, et al. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol. 2006;248(1–2):94–103.\nAl-Sabbagh M, Lam EW-F, Brosens JJ. Mechanisms of endome-trial progesterone resistance. Mol Cell Endocrinol. 2012;358(2):208–215.\nLessey BA, Lebovic DI, Taylor RN. Eutopic endometrium in women with endometriosis: Ground zero for the study of implantation defects. Semin Reprod Med. 2013;31(2):109–124.\nGroothuis PG, Nap AW, Winterhager E, Grummer R. Vascular development in endometriosis. Angiogenesis. 2005;8(2):147–156.\nBourlev V, Volkov N, Pavlovitch S, Lets N, Larsson A, Olovsson M. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction. 2006;132(3):501–509.\nNap AW, Griffioen AW, Dunselman GA, et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab. 2004;89(3):1089–1095.\nBishop LA, Robertson DM, Cahir N, Schofield PR. Specific roles for the asparagine-linked carbohydrate residues of recombinant human follicle stimulating hormone in receptor binding and signal transduction. Mol Endocrinol. 1994;8(6):722–731.\nWesthoff WE, Sloostra JW, Puijk WC, et al. In vitro inhibition of the biological activity of follicle-stimulating hormone by anti-peptide antisera representing the human follicle-stimulating hormone beta subunit sequence 33–53. Biol Reprod. 1997;56(2):460–468.\nDias JA, Campo B, Weaver BA, et al. Inhibition of follicle-stimulating hormone-induced preovulatory follicles in rats treated with a nonsteroidal negative modulator of follicle-stimulating hormone receptor. Biol Reprod. 2014;90(1):1–11.\nde la Rosette J, Davis R III, Frankel D, Kold Olesen T. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer. Int J Clin Pract. 2011;65(5):559–566.\nGhiringhelli F, Isambert N, Ladoire S. Degarelix as a new antian-giogenic agent for metastatic colon cancer? World J Gastroenterol. 2013;19(5):769–772.\nCheong Y, Tay P, Luk F, Gan HC, Li TC, Cooke I. Laparoscopic surgery for endometriosis: How often do we need to re-operate? J Obstet Gynaecol. 2008;28(1):82–85.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nRobin, B., Planeix, F., Sastre-Garau, X. et al. Follicle-Stimulating Hormone Receptor Expression in Endometriotic Lesions and the Associated Vasculature: An Immunohistochemical Study. Reprod. Sci. 23, 885–891 (2016). https://doi.org/10.1177/1933719115623647\nPublished:\nIssue date:\nDOI: https://doi.org/10.1177/1933719115623647","source_license":"CC0","license_restricted":false}